Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy: a study of the Turkish Descriptive Oncological Researches Group

Medical Oncology

Volumn 31, Issue 10, 2014, Pages 1-7

  Tanriverdi, Ozgur ^a   Cokmert, Suna ^b   Oktay, Esin ^c   Pilanci, Kezban Nur ^d   Menekse, Serkan ^e   Kocar, Muharrem ^f   Sen, Cenk Ahmet ^g   Avci, Nilufer ^h   Akman, Tulay ⁱ   Ordu, Cetin ^d   Goksel, Gamze ^e   Meydan, Nezih ^c  

^a MUGLA SITKI KOCMAN UNIVERSITY   (Turkey)

^b KENT HOSPITAL   (Turkey)

^c ADNAN MENDERES UNIVERSITY   (Turkey)

^d ISTANBUL BILIM UNIVERSITY   (Turkey)

^e CELAL BAYAR UNIVERSITY   (Turkey)

^f Education and Research Hospital ^*  (Turkey)

^g MEDICAL PARK HOSPITAL   (Turkey)

^h Medical Oncology Clinic State Hospital   (Turkey)

ⁱ TEPECIK EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Non small cell lung cancer; Prognosis; Serum uric acid

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PACLITAXEL; URIC ACID;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CROSS-SECTIONAL STUDY; DEMOGRAPHY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LUNG CARCINOMA; LEUKOCYTE COUNT; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; THROMBOCYTE COUNT; URIC ACID BLOOD LEVEL; WEIGHT REDUCTION; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; ONCOLOGY; ORGANIZATION AND MANAGEMENT; PATHOLOGY; PROGNOSIS; RISK FACTOR; SECONDARY; SURVIVAL RATE; TURKEY;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LEUKOCYTE COUNT; LUNG NEOPLASMS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM STAGING; PLATELET COUNT; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TURKEY; URIC ACID;

EID: 84919919814     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0217-z     Document Type: Article

References (30)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Berghmans T, Paersmans M, Sculier JP. Prognostic factors in stage III non-small-cell lung cancer: a review on conventional, metabolic and new biological variables. Ther Adv Med Oncol. 2011;3:127–38.
3. Ademuyiva FO, Johnson CS, White AS, Breen TE, Harvej J, et al. Prognostic factors in stage III non-small-cell lung cancer. Clin Lung Cancer. 2007;8:478–82.
4. Berghmans T, Mascaux C, Haller A, Meert AP, von Houtte P, et al. EGFR, TTF-1, and Mdm2 expression in satge III non-small-cell lung cancer: a positive association. Lung Cancer. 2008;62:35–44.
5. Betticher DC, Hsuschmitz SF, Totsch M, Hensen E, Joss C, et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA, pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer. 2006;94:1099–106.
6. Brundage MD, Dovies D, Mackillop WJ. Prognostic factors in non-small-cell lung cancer: a decade of progress. Chest. 2002;122:1037–57.
7. Tanako F, Yanagihana K, Otake Y, Kawano Y, Miyahana R, et al. Prognostic factors in resected pathologic (p-) stage IIIA, N2 non-small cell lung cancer. Ann Surg Oncol. 2004;11:612–8.
8. Martins SJ, Peresna JR. Clinical factors and prognosis in non-small cell lung cancer. Am J Clin Oncol. 1999;22:453–7.
9. Seculier JP, Chansky K, Crowley JJ, van Meerbeeck J, Goldshow P. The impact of additional prognostic factors on survival and their relationship with the anatomical extend of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposal for the 7th Edition. J Thorac Oncol. 2008;3:457–66.
10. Choi YS, Shim YM, Kim J, Kim K. Recurrence-free survival and prognostic factors in resected pN2 non-small cell lung cancer. Eur J Cardiothorac Surg. 2002;22(695–700):11.
11. Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012;1:16–30.
12. Petersson B, Trell E. Raised serum urate concentration as risk factor for premature mortality in middle-age men: relation to death from cancer. Br Med J (Clin Res Ed). 1983;287:7–9.
13. Petersson B, Trell E, Henningsen NC, Hood B. Risk factors for premature death in middle-age men. Br Med J (Clin Res Ed). 1984;288:1264–8.
14. Levine W, Dyer AR, Shekelte RB, Schoenberger JA, Stanler J. Serum uric acid and 11.5-year mortality of middle-age women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol. 1989;42:257–67.
15. Ames BN, Catheart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78:6858–62.
16. Shin HS, Lee HR, Lee DG, Shin JY, Cho KH, et al. Uric acid as a prognostic factor for survival time: a prospective cohort study of terminally ill cancer patients. J Pain Symptom Manage. 2006;31:493–501.
17. Giavonnucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007;83:s836–42.
18. Rose DP, Hoffner SM, Baillargeon J. Adiposity, the metabolic syndrome, and breast cancer in African–American and white American women. Endocr Rev. 2007;28:763–77.
19. Sun AS, Cederboum AI. Oxidoreductase activities in normal rat liver, tumor-bearing rat liver, and hepatoma HC-252. Cancer Res. 1980;40:4677–81.
20. Ikegama T, Natsumeda Y, Weber G. Decreased concentration of xanthine dehydrogenase (EC 1.1.1.204) in rat hepatomas. Cancer Res. 1986;46:3838–41.
21. Lawol AO, Kolude B, Adeyemi BF. Serum uric acid levels in oral cancer patients seen at tertiary institution in Nigeria. Ann Ib Postgrad Med. 2012;10:9–12.
22. Bozkir A, Simsek D, Gungor A, Torun M. Ascorbic acid and uric acid levels in lung cancer patients. J Clin Pharm Ther. 1999;24:43–7.
23. Strasak AM, Rapp K, Hilbe W, Oberaigner W. The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28,000 older Austrian women. Ann Oncol. 2007;18:1893–7.
24. Wıllet WC, MacMahon B. Diet and cancer- an overview (first of two parts). N J Engl Med. 1984;310:633–8.
25. Abdel-Salam OME, Youness ER, Hafez HF. The antioxidant status of the plasma in patients with breast cancer undergoing chemotherapy. J Mol Integr Physiol. 2011;1:29–35.
26. Sevanian A, Davis KJ, Hochstein P. Serum urate as an antioxidant for ascorbic acid. Am J Clin Nutr. 1991;54:1129–11343.
27. Kolonel LN, Yoshisama C, Nomura AM, Stemmermann GN. Relationship of serum uric acid to cancer occurrence in a prospective male cohort. Cancer Epidemiol Biomarkers Prev. 1994;3:225–8.
28. Cetin K, Ettinger DS, Hei YJ, O’Malley CD. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology, and End results Program. Clin Epidemiol. 2011;3:139–48.
29. Franklin WA, Aisner DL, Varella-Garcia M. prognostic patterns in the histology of pulmonary adenocarcinoma. J Clin Oncol. 2012;30:1401–3.
30. Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E, et al. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer. 2014;84:13–22.